Home / Health / CRISPR Gene Therapy Sees Pediatric Expansion
CRISPR Gene Therapy Sees Pediatric Expansion
15 Sep
Summary
- CASGEVY received FDA approval for pediatric use.
- Commercial launch bottlenecks have been addressed.
- Future growth may come from gentler conditioning regimens.
CRISPR Therapeutics is experiencing growing adoption for its gene therapy, CASGEVY, with a recent FDA label expansion to include pediatric patients aged 2 and older. CEO Sam Kulkarni described this pediatric indication as a considerable "tailwind" for the therapy, which is jointly marketed with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia.
Vertex reported approximately $76 million in CASGEVY revenue last quarter, with more than 100 patient initiations each quarter. Kulkarni noted that many initial challenges, such as reimbursement, hospital contracting, and manufacturing capacity, have been overcome. However, the patient treatment journey from initiation to actual treatment can still take six to nine months.
Looking ahead, CRISPR Therapeutics anticipates future growth from gentler conditioning regimens that could significantly reduce hospital stays. The company is also pursuing in vivo hematopoietic stem cell editing, a development that could expand treatment possibilities beyond current markets in the U.S. and Western Europe. Further data updates from pipeline programs are expected by the end of 2026.
